A Turning Point in Synovial Sarcoma – First T-Cell Therapy Moves Toward FDA Approval
In this article
Synovial sarcoma is a difficult-to-treat soft tissue cancer that usually affects young adults. It begins in synovial tissues around joints in different parts of the body and can metastasize. For many years, treatment has seen little major progress, leaving patients with limited options. However, afami-cel , developed by Adaptimmune Therapeutics and recently accepted for priority review by the United States Food and Drug Administration (FDA), is reshaping the science and hope in this field.
Afami-cel and Adaptive Cell Therapy
Afami-cel is a genetically engineered T-cell receptor (TCR) T-cell therapy offering new hope against solid tumors, originating in tissues or organs, including synovial sarcoma.
Adaptive cell therapy involves modifying and enhancing a patient's own immune cells, usually T cells, in a laboratory, then returning them to target cancer as a form of immunotherapy . This method strengthens the patient's own defenses by programming the immune system to fight cancer directly.
Afami-cel is designed to target a protein called MAGE A4. MAGE A4 is a tumor antigen located inside cells, particularly in the nucleus of cancer cells. It is overexpressed in certain cancers and can be targeted by engineered T-cell therapies to selectively destroy those cells.
Designed to target MAGE A4 and intended as a single-dose treatment for advanced synovial sarcoma, this innovative therapy could become the first effective new approved option in a decade. It represents a first in synovial sarcoma treatment since the approval of pazopanib (Votrient) in 2012.
The image below shows how an engineered T-cell receptor (TCR) therapy such as afami-cel works at the cellular level.
- Identifying the target protein: Afami-cel recognizes a target protein such as MAGE A4, found particularly in cancer cells and rarely in normal cells.
- Processing the protein: The intracellular proteasome breaks down the target protein into peptide fragments.
- Forming the HLA–peptide complex: Processed peptide fragments combine with HLA (Human Leukocyte Antigen) molecules on the cell surface. This complex is transported to the cell surface for recognition by T cells.
- Recognition and interaction through TCR: T-cell receptors (TCRs) on engineered T cells recognize the HLA–peptide complex and bind specifically to cancer cells.
- Acting against cancer cells: TCR binding to the HLA–peptide complex triggers T-cell activation to destroy cancer cells. This kills the cancer cells, causing the tumor to shrink or disappear.
This mechanism allows treatments such as afami-cel to target only cancer cells without harming healthy cells, providing effective cancer treatment.
Clinical Research and Results
Positive data from cohort 1 of the pivotal SPEARHEAD-1 trial showed that afami-cel met its primary efficacy endpoint.
In heavily pretreated patients with advanced synovial sarcoma, the study found:
- An overall response rate of 39%, and
- A median response duration of approximately 12 months.
- Median overall survival was approximately 17 months , and
- 70% of patients responding to afami-cel were alive 2 years after treatment.
These results underscore afami-cel's potential as an innovative new treatment option for patients with synovial sarcoma.
The FDA BLA Application and Its Significance
A Biologics License Application (BLA) is part of the FDA approval process for biological products. Acceptance of afami-cel's BLA for priority review means its potential approval process will be expedited. This is an important step in Adaptimmune's effort to redefine synovial sarcoma treatment. The Prescription Drug User Fee Act (PDUFA) target decision date is 4 August 2024, the deadline by which the FDA is expected to decide on afami-cel's approval.
Conclusion
Acceptance of Adaptimmune's FDA BLA for afami-cel could redefine treatment approaches for people with synovial sarcoma. This long-awaited advance heralds a promising new era in treating advanced disease. Afami-cel is an important step toward demonstrating the effectiveness of engineered T-cell therapies in solid tumors and, if approved, will become a significant option for patients.
Sources
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.